Market Place
Sourcing Support
Hutchison China Meditech Showcases Data At AACR Annual Meeting
09 Apr 2026 //
PHARMIWEB
HUTCHMED Updates On TAZVERIK Oncology Product In China
09 Mar 2026 //
GLOBENEWSWIRE
HUTCHMED Highlights SACHI Phase III Results in the Lancet
14 Jan 2026 //
PHARMIWEB
Hutchmed Heats Up Autoimmune Race With Phase 3 Win
07 Jan 2026 //
FIERCE BIOTECH
HUTCHMED Reports Positive Phase III Data for Sovleplenib in AIHA
06 Jan 2026 //
GLOBENEWSWIRE
HUTCHMED Starts Phase III Trial For Surufatinib And Camrelizumab
04 Jan 2026 //
GLOBENEWSWIRE
Hutchmed`s Fanregratinib NDA Accepted In China With Priority
29 Dec 2025 //
GLOBENEWSWIRE
HUTCHMED Starts Global Trials For Solid Tumor Drug HMPL-A251
16 Dec 2025 //
GLOBENEWSWIRE
Hutchmed Expands Its NRDL Coverage, Joins First Commercial List
07 Dec 2025 //
GLOBENEWSWIRE
HUTCHMED Completes Enrollment In SAFFRON Ph III Trial
04 Nov 2025 //
GLOBENEWSWIRE
Hutchmed Highlights Pipeline & Business Progress
02 Nov 2025 //
GLOBENEWSWIRE
HUTCHMED Presents HMPL-A251 Data at AACR-NCI-EORTC Conference
23 Oct 2025 //
PHARMIWEB
Hutchison China Meditech Showcases HMPL-A251 Data
22 Oct 2025 //
GLOBENEWSWIRE
HUTCHMED to Present FRUSICA-2 Trial Data at ESMO 2025
13 Oct 2025 //
GLOBENEWSWIRE
Hutchmed Showcases Clinical Data At Esmo Congress 2025
01 Oct 2025 //
GLOBENEWSWIRE
HUTCHMED Finishes Enrollment for SANOVO Phase III Trial in China
19 Aug 2025 //
GLOBENEWSWIRE
Hutchmed, Innovent File NDA in China for Renal Cell Carcinoma
06 Jun 2025 //
GLOBENEWSWIRE
Hutchmed Completes Patient Enrollment for Savolitinib Study
21 Apr 2025 //
GLOBENEWSWIRE
HUTCHMED Highlights Savolitinib SAVANNAH Ph 2 At ELCC 2025
19 Mar 2025 //
GLOBENEWSWIRE
Innovent and HUTCHMED announce FRUSICA-2 study results
18 Mar 2025 //
PR NEWSWIRE
HUTCHMED and Innovent announce FRUSICA-2 study success in China
18 Mar 2025 //
GLOBENEWSWIRE
HUTCHMED Gets NMPA Approval For ORPATHYS® In MET Exon 14 NSCLC
13 Jan 2025 //
GLOBENEWSWIRE
Hutchmed & Innovent Announce NMPA Approval for Elunate in Cancer
03 Dec 2024 //
GLOBENEWSWIRE
HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
08 Sep 2024 //
GLOBENEWSWIRE
Hutchmed in collab with Hengrui initiate phase II/III trial of surufatinib
16 May 2024 //
PHARMABIZ
Inmagene Exercises Option to Obtain Worldwide License for IMG-007 and IMG-004
02 Feb 2024 //
PR NEWSWIRE
HUTCHMED has Completed Enrollment of Ph II/III of Fruquintinib with Sintilimab
12 Dec 2023 //
GLOBENEWSWIRE
HUTCHMED Highlights Presentation of Results from Phase IIIb Trial of Savolitinib
12 Sep 2023 //
GLOBENEWSWIRE
HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
29 Aug 2023 //
PRESS RELEASE
HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
28 Aug 2023 //
GLOBENEWSWIRE
Hutchmed Receives BTD for Fruquintinib Combination with Sintilimab
19 Jul 2023 //
GLOBENEWSWIRE
Hutchmed Initiates Registration Phase Enrollments of HMPL-453
04 Apr 2023 //
GLOBENEWSWIRE
